Sanofi India posts Q4 CY22 PAT at Rs. 130.9 Cr
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Ayurveda is one of the most advanced sciences of its times
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
This artificial RNA ligase has higher thermostability than natural RNA ligase
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
Subscribe To Our Newsletter & Stay Updated